At the molecular level, SLOS is caused by pathogenic variants in the DHCR7 gene located on chromosome 11q13.4. This gene encodes the enzyme (also known as 7-dehydrocholesterol reductase). This enzyme catalyzes the final step of cholesterol biosynthesis: the reduction of the double bond at the C7-C8 position of 7-dehydrocholesterol (7-DHC) to produce cholesterol.
Cholesterol is not merely a structural lipid; it is a critical and a morphogen . Its deficiency explains the majority of the syndromic features. Fisiopatologia De Smith Thier
In a healthy individual, the reaction proceeds as: At the molecular level, SLOS is caused by
The pathophysiology of Smith-Lemli-Opitz syndrome is a paradigm of how a single enzymatic defect in lipid metabolism can produce a multisystem developmental disorder. The syndrome is driven by two synergistic mechanisms: (especially Shh signaling and membrane integrity) and gain of toxic precursor effects (oxidative stress from 7-DHC). Understanding these mechanisms has led directly to therapeutic strategies, including dietary cholesterol supplementation, simvastatin to reduce 7-DHC, and antioxidant therapy. However, since cholesterol does not cross the blood-brain barrier effectively, CNS pathology remains the greatest challenge. Ongoing research focuses on neurosteroid replacement and gene therapy to rescue the cerebral phenotype. For the clinician, recognizing SLOS as a cholesterol biosynthesis disorder is the first step toward accurate diagnosis, genetic counseling, and targeted metabolic management. Note on terminology: The phrase "Fisiopatologia De Smith Thier" likely refers to Smith-Lemli-Opitz syndrome . There is no recognized "Smith-Thier" syndrome; it is almost certainly a phonetic or typographical variant of the correct eponym. Cholesterol is not merely a structural lipid; it
Understanding the pathophysiology of SLOS requires a deep dive into the mevalonate-cholesterol biosynthesis pathway and the pleiotropic effects of cholesterol deficiency during embryogenesis and postnatal development.
| System | Pathophysiology | Clinical Manifestation | | :--- | :--- | :--- | | | Shh deficiency → abnormal ventral patterning; cholesterol lack → poor myelination. | Microcephaly, agenesis of corpus callosum, cerebellar hypoplasia, intellectual disability, autism, self-injurious behavior. | | Craniofacial | Shh deficiency → impaired midline fusion. | Broad nasal tip, ptosis, micrognathia, cleft palate, bifid uvula. | | Limb | Aberrant Shh gradient in zone of polarizing activity (ZPA). | 2-3 toe syndactyly (pathognomonic), postaxial polydactyly, short thumbs. | | Gastrointestinal | Lack of cholesterol → smooth muscle dysmotility; Shh deficiency → abnormal gut looping. | Severe gastroesophageal reflux, pyloric stenosis, Hirschsprung disease (5-7% of cases). | | Genitourinary | Impaired androgen synthesis (cholesterol precursor for all steroids). | Hypospadias, cryptorchidism, ambiguous genitalia in 46,XY males; uterus didelphys in females. | | Skin/Adnexa | Abnormal sterol composition in keratinocyte membranes. | Photosensitivity (due to 7-DHC accumulation), dry skin, syndactyly of toes. |
The Pathophysiology of Smith-Lemli-Opitz Syndrome: From Cholesterol Deficiency to Clinical Dysmorphology